Introduction
Prostate cancer is the most commonly diagnosed noncutaneous neoplasm in adult males and the second leading cause of cancer mortality among American males. It is estimated that in 2005, 233 090 men will be newly diagnosed with prostate cancer and 30 350 men are projected to die from their cancer. 1 Although conventional therapy, radical prostatectomy, or radiation therapy (XRT), can be effective treatment for many localized tumors, the prognosis is poor for patients with recurrent or metastatic disease. Once prostate cancer has metastasized, there are no curative therapies with hormonal therapy offering symptomatic relief. The continued high mortality from prostate cancer emphasizes the need for the development of effective therapies for metastatic disease.
2 Antimetastatic therapy will require either systemic delivery or localized delivery of an agent that activates a systemic response. Activation of the host immune system with immunomodulatory agents such as cytokines may achieve this effect.
We have pioneered gene therapy approaches using adenoviral vector delivery in situ for prostate cancer, and have extensive preclinical and clinical experience with adenoviral vector delivery of the herpes simplex virus (HSV) thymidine kinase (tk) gene followed by the prodrug ganciclovir (GCV). The results of our phase I/II clinical trials have shown evidence of prostate cancer cell apoptosis and immune cell activation following this therapy. 3, 4 We also have combined this therapy with radiotherapy, 5, 6 and demonstrated that this combination further increased the total CD8+ T cells and activated CD4+ T cells in the peripheral blood. Interleukin-12 (IL-12) is a 79-kDa heterodimeric multifunctional cytokine consisting of two subunits (p35 and p40) with its primary action, directing Th1 differentiation of the immune response. 8 Interleukin-12 was found to have potent antitumor effectiveness in a variety of preclinical tumor models. 9 However, the use of systemic IL-12 clinically has been limited due to toxic side effects. 10, 11 Adenoviral delivery of IL-12 has been proposed as a means to reduce this toxicity due to the restricted sites of delivery and expression, and numerous preclinical studies confirmed antitumor activities (reviewed in Thompson et al. 12 ). We have recently initiated a clinical trial that involves in situ delivery of a recombinant adenoviral vector expressing the human IL-12 genes. This clinical trial is based on preclinical studies that demonstrated that adenoviral vector delivery of mouse IL-12 (AdmIL-12) can significantly suppress tumor growth, suppress spontaneous and experimental lung metastases, and enhance survival in mouse orthotopic models of metastatic prostate cancer. [13] [14] [15] This paper describes the preclinical studies that evaluated the potential benefit of combining IL-12 gene therapy with radiation for prostate cancer. We demonstrate enhanced effects both in vitro and in vivo following AdmIL-12+radiation (XRT) in a metastatic mouse prostate cancer cell model.
Results

In vitro effects of AdmIL-12+XRT
To determine if adenoviral vector mediated expression of IL-12 exhibits combinatorial effects with radiation in vitro, we used the bone metastasis derived mouse prostate cancer cell line 178-2 BMA. 16 Cells were infected with AdmIL-12 or Adbgal at an multiplicity of infection (moi) of 100, then the next day irradiated at single doses of 5, 10, and 15 Gy. The cells were then plated for clonogenic survival analysis (Figure 1a ) or for determination of apoptosis (Figure 1b ). In the clonogenic survival analysis, the colony number was suppressed in a dose dependent manner by radiation. The combination AdmIL-12+XRT significantly suppressed colony formation at each radiation dose compared with uninfected or Adbgal infected cells (Po0.05, unpaired t-test).
In the apoptosis analysis, AdmIL-12+XRT dramatically increased the number of apoptotic cells when combined with a high dose (15 Gy) of radiation (Po0.0001, compared with uninfected or Adbgal). Interestingly, treatment of the cells with recombinant mouse IL-12 protein (rmIL-12) both before and after radiation also significantly increased the number of apoptotic cells at 15 Gy of radiation (Po0.01, compared with uninfected, Figure 1b ). The level of IL-12 secreted into the media was determined by enzyme-linked immunosorbent assay (ELISA) 48 h after radiation (Figure 1c ). Secreted IL-12 was not detected in uninfected or Adbgal infected (moi 100) cells or in cells treated with rmIL-12. An moidependent increase in secreted IL-12 was seen in AdmIL-12 infected cells. Interestingly, radiation significantly increased IL-12 secretion in cells infected at either moi 25 or 50 (Po0.01, compared with each 0 Gy of radiation). The only significant increase in IL-12 secretion observed at a given moi when the radiation dose was increased above 5 Gy was at 25 moi, AdmIL-12+15 Gy radiation also showed significantly increased mIL-12 secretion compared to AdmIL-12+5 Gy radiation (Po0.05).
AdmIL-12+XRT increases tumor necrosis factor-a expression in vitro
To evaluate the potential apoptotic pathways activated in the combined AdmIL-12+XRT treated cells, we determined the expression level of selected genes by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Cells were infected with AdmIL-12 or Adbgal at an moi of 100, or treated with rmIL-12, and Figure 1 In vitro combinatorial effects of AdmIL-12+XRT. Cells were seeded in 10-cm plates at 2 Â 10 6 cells/plate. The next day, they were infected with AdmIL-12 or Adbgal at an moi of 100. At 24 h after vector infection, cells were irradiated several doses and reseeded. Colonies were stained 12 days after irradiation (a), and apoptotic cells were determined 2 days after irradiation (b). *Po0.05; **Po0.0001; ***Po0.01. (c) mIL-12 secretion into culture media (pg/ml) 48 h after irradiation. Bars, s.e. *Po0.01 versus 0 Gy; **Po0.05 versus 5 Gy. . The AdmIL-12 doses used were not curative but a statistically significant tumor growth delay was observed with the highest AdmIL-12 dose on day 14 (P ¼ 0.0211, results not shown). To establish a radiation dose subcutaneous mouse prostate tumors were irradiated with 5, 10, or 15 Gy as a single fraction. Tumor growth delay was observed with all three doses, but the growth delay for the two higher dose groups were statistically significant (Po0.0001, compared with 0 Gy; results not shown). There were no observed systemic toxicities with any of the radiation doses. A dose of 5 Â 10 8 PFU and 5 Gy per tumor was chosen for subsequent in vivo studies.
For combination therapy, tumors were injected with 5 Â 10 8 PFU of AdmIL-12 or Adbgal 12-14 days after subcutaneous inoculation of 178-2 BMA cells. Forty-eight hours after vector injection the tumor was irradiated at a single dose of 5 Gy. Tumor size was measured with calipers every other day to monitor tumor growth ( Figure 3a ). By day 4 there was significant growth suppression in the AdmIL-12+XRT group, the AdmIL-12 monotherapy group, and the Adbgal+XRT group compared to the control Adbgal group (P ¼ 0.0015, 0.0028, and 0.0483, Fishers PLSD test). Growth suppression with AdmIL-12+XRT was obvious for at least 2 weeks before the tumors began to grow. Overall AdmIL-12+XRT significantly suppressed the growth of primary tumors compared with control Adbgal vector, Adbgal+XRT, or AdmIL-12 as monotherapy (Po0.0001, 0.0004, and 0.0456, respectively, analysis of variance).
At three defined time points after vector injection, selected mice from each treatment group were analyzed extensively. As presented in Figure 3b , the tumor wet weight was significantly suppressed in the AdmIL-12+XRT treated group compared with other selected groups on day 4 (P ¼ 0.0311, compared with Adbgal), day 7 (P ¼ 0.0005 compared with Adbgal and P ¼ 0.0061 compared with XRT), and day 14 (Po0.0001 when compared with Adbgal or XRT and P ¼ 0.0019 compared to AdmIL-12).
To evaluate potential antimetastatic effects of AdmIL-12+XRT in the 178-2 BMA subcutaneous model, we analyzed the extent of lung metastases in AdmIL-12+XRT, Adbgal, XRT, and AdmIL-12 treated animals on 14 days after vector injection. AdmIL-12+XRT significantly suppressed spontaneous lung metastases compared with Adbgal or XRT (P ¼ 0.0003 and 0.0377, respectively; Figure 4a ). In separate experiments, AdmIL-12+XRT significantly suppressed pre-established Twenty-four hours after vector infection, cells were irradiated and reseeded. Total RNA was collected from duplicate plates 48 h after irradiation, and mRNA levels were determined by quantitative RT-PCR for mouse TNF-a (a), mouse Fas (b), and mouse FasL (c).
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lung metastases compared with Adbgal (P ¼ 0.0479, Figure 4b ). In this pre-established lung metastasis assay, there was no significant difference for AdmIL-12+XRT compared to Adbgal+XRT or AdmIL-12. Figure 5 presents a cumulative Kaplan-Meier survival plot for animals with subcutaneous tumors treated with Adbgal, XRT, AdmIL-12, or AdmIL-12+XRT. Mean survival times for the control groups with subcutaneous 178-2 BMA tumors treated with Adbgal, XRT, or AdmIL-12 were 18.570.7, 22.671.1, or 23.871.2 days, respectively. In the combined AdmIL-12+XRT treatment group, mean survival time was 35.173.7 days. There was a statistically significant difference between the AdmIL-12+XRT group and the Adbgal, XRT, or AdmIL-12 groups by Mantel-Cox log-rank analysis (Po0.0001, 0.0003, and 0.0035, respectively). At necropsy, there was no obvious cause of death other than extensive tumor load, splenic trauma, or abundant ascites. One animal with AdmIL-12+XRT treated subcutaneous tumor survived long-term. 
. A significant survival advantage was observed in the AdmIL-12+XRT group (*Po0.01, log-rank test).
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AdmIL-12+XRT induces a systemic immune response
We confirmed that prostatic expression of AdmIL-12 led to systemic levels of IL-12 by measuring serum levels at each time point (Figure 6a ). On day 4, the level of IL-12 in the AdmIL-12 group was 113 pg/ml (Po0.05, compared with Adbgal or XRT alone). The AdmIL-12+XRT group was only slightly elevated to 84 pg/ml on day 4. On day 7, the AdmIL-12 group was 245 pg/ml and AdmIL-12+XRT group was 265 pg/ml (Po0.05, compared with Adbgal or XRT and Po0.05, compared with Adbgal or XRT, respectively). On day 14, the AdmIL-12+XRT group continued to have a high level of IL-12 (183 pg/ml; Po0.05, compared with Adbgal, XRT, or AdmIL-12).
To Figure 6b ). Interestingly, NK activities in AdmIL-12+XRT group were not apparent on day 4. In splenocytes isolated from mice 7 days after vector injection, NK activities in the AdmIL-12+XRT group increased whereas those in the AdmIL-12 group decreased (Figure 6c ). However, there were no statistically significant differences on day 7. Significantly increased NK activities were demonstrated in splenocytes isolated from AdmIL-12+XRT combined therapy mice 14 days after vector injection compared with Adbgal, XRT, or AdmIL-12 treatment groups (Po0.05, unpaired t-test at an E:T ratio of 100:1 compared with Adbgal, XRT, or AdmIL-12, Po0.05, unpaired t-test at an E:T ratio of 50:1 compared with AdmIL-12; Figure 6d ).
To further examine the role of NK cells, we treated mice with either control rabbit serum (Figure 7a ) or antiasialo GM1 serum to deplete NK cells in vivo ( Figure  7b ). The tumor bearing mice were treated with Adbgal or AdmIL-12 followed by 0 or 5 Gy then evaluated 14 days after vector injection. Natural killer activities were minimal in all mice that received antiasialo GM1, but elevated in mice that received control serum and AdmIL-12 treatment either with or without XRT. The NK activities in the control serum treated animals were similar to the NK activity observed in experiments at day 14 ( Figure 6d ). There was no effect of NK depletion on tumor wet weight (data not shown). However, NK depletion resulted in significant attenuation in the reduction in the number of spontaneous lung metastases following AdmIL-12 treatment either without (P ¼ 0.0312) or with XRT (P ¼ 0.0325) (Figure 7c ).
Discussion
In situ delivery of cytotoxic/immunostimulatory genes into prostate cancer holds promise for treating localized disease with the potential for systemic therapeutic effects. 2, 17 In parallel with the development of gene therapy, there have been significant advances in the 18 New computer-assisted conformal means of delivering radiation specifically to target tumor tissues such as intensity modulated radiotherapy can provide dose escalation, while keeping the radiotherapy dose below the radiation threshold for adjacent normal tissue. 18 Importantly, there are significant advantages for combining gene therapy with XRT for enhancing the therapeutic index in several malignancies. 19, 20 In situ gene therapy using intraprostatic injection of an adenoviral vector encoding the HSV-tk transgene followed by systemic prodrug therapy has been tested extensively in preclinical studies and clinical trials for prostate cancer at Baylor College of Medicine. [3] [4] [5] [6] [21] [22] [23] From a total number of approximately 200 men who have received gene therapy at our institution, most received radiotherapy subsequent to the gene therapy as a combination approach. 5, 6, 23 In other studies, 11 men with metastatic prostate cancer have received injections into prostatic lymph nodes or bone metastases of an adenoviral vector with an osteocalcin promoter-driven HSV-tk gene followed by valacyclovir with no adverse events reported. 24 A replication competent adenoviral vector with two cytotoxic genes, HSV-tk and cytosine deaminase, has also been safely administered intraprostatically to 15 patients who also received concurrent systemic prodrug treatment, valganciclovir and 5-fluorocytosine, together with conformal XRT to the prostate. 25 Although intratumorally or intralesionally injected adenoviral vectors have the potential to leak into the systemic circulation, infecting parenchymal organs like liver and spleen, [26] [27] [28] the limited toxicity in the HSV-tk gene therapy clinical trials suggests that in situ delivery may provide a safe approach.
We recently observed increased levels of serum IL-12 within 1 week after vector injection in our phase I/II clinical trials of in situ adenoviral vector-mediated HSVtk gene therapy followed by the prodrug ganciclovir. 29 Interestingly, there was a concomitant decrease in the plasma levels of TGF-b1. 29 In our preclinical studies of AdmIL-12 gene therapy for orthotopic murine prostate tumors generated by the RM-9 tumor cell line, a single orthotopic injection of AdmIL-12 significantly suppressed tumor growth, increased the survival time, suppressed pre-established lung metastases, and reduced the number of spontaneous regional lymph node metastases. 13 We have also demonstrated that orthotopic AdmIL-12 is as effective as a vector that combines IL-12 with the co-stimulatory molecule CD80 (B7-1) for suppression of lung metastases, but not quite as effective for survival. 14 We have further tested combined in situ AdmIL-12 with AdHSV-tk+GCV gene therapy in the RM-9 mouse prostate cancer model and documented that AdmIL-12 alone had somewhat superior activity with regard to local cytotoxicity, overall prolongation of survival time and antimetastatic effects. 15 Adenoviral vector mediated in situ interleukin-12 is also effective as a cell-based vaccine with one fifth of the mice fully protected from subsequent challenge with an orthotopic tumor.
14 More recently, we demonstrated that AdmIL-12 modified dendritic cells 30 or macrophages 31 can be used therapeutically for cell based prostate cancer therapy. We have recently initiated a Phase I clinical trial using an adenoviral vector containing the human IL-12 genes in men with recurrence of their prostate cancer following XRT. Thirty-three patients with liver, colorectal, or 
32
Since we previously demonstrated that combined HSV-tk+GCV gene therapy and radiotherapy suppressed tumor growth increased the survival, and suppressed pre-established lung metastases in the RM-1 mouse prostate cancer model, 33 we undertook the present study to evaluate the combined therapeutic approach of radiation and AdmIL-12 gene therapy. Separate studies with the RM-1 model have indicated that NK cells are a major source of therapeutic benefit following HSVtk+GCV gene therapy. 34 In this study, we used the 178-2 BMA subcutaneous prostate cancer cell model system to test the antitumoral and antimetastatic activities of intratumoral injection of AdmIL-12 combined with radiotherapy delivered as a single fraction of 5 Gy. The results clearly demonstrated that combination AdmIL-12+XRT therapy produced significantly greater antitumor and antimetastatic activities compared with control Adbgal alone or combined with XRT, or compared to AdmIL-12 monotherapy. Only AdmIL-12+XRT therapy was effective at prolonging survival. AdmIL-12 monotherapy was more effective than radiotherapy alone at inhibiting local tumor size and spontaneous metastases, but did not offer a survival benefit in this prostate cancer model. The survival benefit of AdmIL-12+XRT could be related to the prolongation of serum IL-12 levels and NK cell activities relative to monotherapy (see Figure 6 ). Consistent with previous results in the RM-9 model, 13 the highest level of NK cell activity following AdmIL-12 monotherapy was on day 3. Interestingly, the combination of AdmIL-12+XRT resulted in baseline levels of NK activity at this time point yet had higher levels at later time points (Figure 6b-d) . In our opinion, this attenuation of an immediate immune response could be related to widespread apoptotic activities in the tumor microenvironment immediately following combination therapy that is sufficient to inhibit or eradicate immune cells pre-existing in the tumor yet provides a stimulus for later activation of an immune response. Interestingly in our clinical trials of AdHSV-tk+GCV combined with radiation, we observed increased activated CD8+ and CD4+ T cells in the peripheral blood of patients 2 weeks after initiation of therapy. 7 We demonstrated that the combination of AdmIL-12+XRT induces apoptosis and expression of TNF-a in vitro. It has previously been reported that exogenous expression of interleukin-12 leads to upregulation of the Fas/FasL pathway in RM-9 mouse prostate cancer cells; 35 however, in 178-2 BMA cells used in this study we did not detect increased Fas or FasL with AdmIL-12 but did detect slightly increased TNF-a. Other cancer cells, for example, breast cancer and osteosarcoma, may upregulate Fas in response to IL-12. 36 Radiation alone also is known to upregulate TNF-a 37 and the Fas/FasL pathway in cells with wild-type p53. 38, 39 We demonstrated modest radiation dependent increases in TNF-a, Fas, and FasL, which may potentiate antitumor immune responses. 40 Our results with recombinant IL-12 in vitro confirmed that this cytokine when combined with radiation has the ability to induce apoptosis, and is a potent inducer of TNF-a, Fas, and FasL mRNAs in 178-2 BMA prostate cancer cells. We did not use recombinant IL-12 in vivo because its clinical use has been hampered by toxic side effects. 10, 11 Systemic IL-12 has been combined with radiotherapy in other murine tumor models for lung cancer, bladder cancer, and melanoma with impressive results. [41] [42] [43] In this paper, we demonstrate that the combination of AdmIL-12 gene therapy and radiotherapy had significant local antitumor and systemic antimetastatic activities in a preclinical model of metastatic prostate cancer. In vivo depletion of NK cells confirmed that NK cells were predominantly responsible for the antimetastatic activities associated AdmIL-12 gene therapy consistent with previous studies in orthotopic mouse prostate cancer models. 13, 15 Adenoviral vectors with the IL-12 genes have been combined with radiotherapy for local and distant control of melanoma or sarcoma in other preclinical studies. [44] [45] [46] These studies provide a rationale for combining XRT with AdIL-12 gene therapy for men with prostate cancer.
Materials and methods
Cells and adenoviral vectors
The mouse metastatic prostate cancer cell line 178-2 BMA 16 was derived from a bone metastasis obtained from Zipras/myc-infected urogenital sinus tissue from p53 heterozygous 129/Sv mice in the metastatic mouse prostate reconstitution (MPR) model system. 47 Cells were grown in complete medium, Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, 10 mM HEPES, penicillin (100 U/ml), and streptomycin (100 mg/ml). All chemicals for cell culture were obtained from GIBCO (Gaithersburg, MD, USA). The adenoviral vector expressing the mouse IL-12 genes (AdmIL-12) was provided by Dr Frank Graham and prepared as described. 13 A control adenoviral vector containing the b-galactosidase gene, Adbgal, was prepared as previously described. 48 Each adenoviral vector was titered by plaque assay on 293 cells with the titer expressed as PFU.
In vitro studies 178-2 BMA cells were infected at an moi of AdmIL-12 or Adbgal of 100 in serum-free medium for 3 h, after which the medium was replaced with complete medium. In selected experiments, recombinant mouse IL-12 protein (rmIL-12, R&D Systems) was added to complete medium at 5 ng/ml. Twenty-four hours after vector infection, cells were trypsinized and irradiated at single doses of 5, 10, and 15 Gy. Media was sampled from each of the wells at 24 and 48 h after irradiation.
For clonogenic survival, one percent of the original cells were reseeded on a 10-cm plate after irradiation and incubated for 12 days. Colonies were stained with 0.1% methylene blue in 50% methanol and counted. Data are from three or more independent groups. For apoptosis analysis, cells were reseeded in a 96-well plate after irradiation and incubated for 48 h. Apoptotic morphology was analyzed with fluorescence microscopy following incubation with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) at 0.2 mg/ml. The percentage of apoptotic cells was determined from the ratio of apoptotic nuclei in three randomly selected microscope fields as previously described. 49 
IL-12 gene therapy and radiotherapy T Fujita et al
Total RNA was isolated from cells 48 h after in vitro irradiation by using a RiboPure RNA Isolation kit (Ambion, Austin, TX, USA). TaqMan one-step PCR master mix reagent (Applied Biosystems, Foster City, CA, USA) was used for reverse transcription and PCR with 40 ng total RNA. The primers and probes, mouse TNF-a, mouse Fas, and mouse FasL were obtained from the Assays-on-Demand Service (Applied Biosystems). The relative expression of each mRNA was determined by using threshold cycle comparisons to the standard curve method described by the manufacturer and normalized to 18S RNA as described. 50 In vivo studies After trypsinization, 178-2 BMA cells were resuspended in Hanks' balanced salt solution (HBSS) at 5 Â 10 4 cells in 50 ml. Tumors were established in 4-6-month-old syngeneic 129/Sv mice by subcutaneous injection. Tumors were established in the hind flank to avoid complications of scatter radiation damage to viscera as previously described. 33 This cell dose resulted in tumors of 50-60 mm 3 after 12-14 days at which time AdmIL-12 was injected as described below. The AdmIL-12 dose was determined by dose escalation studies using doses from 1 Â 10 8 to 1 Â 10 9 PFU in 50 ml per tumor. A 30-gauge needle was injected through an intradermal tract before entering the tumor mass to minimize leakage of the vector when the needle was withdrawn.
Radiation dose escalation studies were performed to determine a subtherapeutic radiation dose that would allow analysis of potential cooperative effects between gene therapy and XRT. 33, 51 Tumors were irradiated using an orthovoltage X-ray generator at doses of 5, 10, and 15 Gy. Appropriate shielding of the surrounding tissues was implemented to avoid unnecessary exposure of the viscera to radiation damage. Forty-eight hours after vector injection, tumors were irradiated at a single dose of 5 Gy. Tumor cell injections, vector inoculations, and XRT were performed under general anesthesia using sodium pentobarbital at a dose of 50 mg/g. In a model of pre-existing lung metastases each mouse received a tail vein injection of 5000 178-2 BMA cells in 100 ml HBSS 7 days after the subcutaneous tumor inoculation and was subsequently treated with AdmIL-12 and XRT.
Tumor size was measured every other day in two perpendicular axes with vernier calipers. Tumor volumes were calculated by the formula of a rotational ellipsoid: (m 1 2 Â m 2 Â 0.5236), where m 1 represents the shorter axis and m 2 the longer axis. 52 Animals were killed on day 4, 7, or 14 after vector injection for a complete analysis of therapeutic effects. For survival analysis, animals were evaluated at death or euthanized when tumor size exceeded 25 mm maximum diameter in any axis. Sample size was 5-8 mice per treatment group. All animals underwent a careful necropsy for gross metastases and the primary tumor and spleen were removed and weighted. The spleen was placed in sterile medium and the splenocytes purified for NK activity as determined by lysis of 51 Cr-labeled YAC cells. 13 Blood was drawn from the inferior vena cava at the time of euthanasia and allowed to clot, and the serum was collected after centrifugation. Serum or tissue culture supernatant medium was stored at À801 until the level of IL-12 was determined by ELISA (BioSource International, Camarillo, CA, USA). A portion of each tissue was fixed in formalin, paraffin embedded, cut into 5-mm sections, and stained with hematoxylin and eosin (H&E) for histologic examination. Tissue sections were also evaluated for apoptosis by the TUNEL (TdT (terminal deoxynucleotidyltransferase)-mediated dUTP nickend labeling) technique 53 as previously described. 54 Tissues were also frozen in optimal cutting temperature (OCT) compound, cut into 6-mm sections, and fixed with acetone-methanol for quantitative immunohistochemical staining. 55 The lung were removed and placed in Bouin's solution for fixation. The next day, two independent observers counted the total number of spontaneous or pre-existing metastases with the aid of a dissecting microscope, and the average of the two counts was reported. 13 In vivo depletion of NK cells was essentially as previously described. 13, 15 Tumors were initiated as described above and the mice given an i.p. injection of 200 mg of either antiasialo-GM1 or control rabbit IgG 1 day before vector injection then 1, 5, and 10 days after vector injection.
Mice were maintained in facilities accredited by the American Association for Accreditation of Laboratory Animal Care, and all experiments were conducted in accordance with the principles and procedures outlined in the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
Statistical analysis
Analysis of variance was used to make comparisons between the means. Kaplan-Meier survival analysis was evaluated with log-rank Mantel-Cox test. All analyses were performed with StatView 5.0 (SAS Institute, Cary, NC, USA).
